Eris Therapeutics Limited has been assigned an IND AA/Stable/IND A1+ rating by India Ratings and Research (Ind-Ra) for its bank loan facilities amounting to ₹1,000 million. This rating reflects the company’s robust financial health and strong operational performance.
In addition to the newly assigned rating, Ind-Ra has affirmed the same rating for Eris Therapeutics‘ existing bank loan facilities, which have been reduced from ₹4,686 million to ₹4,200 million. The affirmation underscores the company’s sustained operational excellence and strategic positioning within the Indian pharmaceutical market.
The rating actions are based on the analytical approach that fully consolidates Eris Therapeutics’ 100% parent company, Eris Lifesciences Limited, along with its subsidiaries. This consolidation is due to the strong legal, operational, and strategic linkages among them. Eris Lifesciences has demonstrated a strong competitive position, with significant improvements in its operating profile, evidenced by a rise in EBITDA to ₹8.5 billion in the first nine months of FY26.
Eris Lifesciences has expanded its manufacturing base and diversified its product portfolio, including injectables and insulin alongside oral formulations. The company has also increased its geographic diversification, with exports now accounting for 11% of revenue in the first nine months of FY26.
Ind-Ra anticipates that Eris Lifesciences will continue to support Eris Therapeutics through equity or preferential shares for capital expenditure and working capital needs over the medium term. This support is facilitated by Eris Lifesciences’ centralised treasury and management control, ensuring that Eris Therapeutics’ financial requirements are met efficiently.
The rating agency also noted Eris Lifesciences’ strategic focus on mergers and acquisitions (M&As) as a key driver of revenue and EBITDA growth. The company’s recent acquisitions have strengthened its competitive position and expanded its capabilities in high-growth segments.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).